OLD Mission Capital LLC purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 9,064 shares of the medical equipment provider’s stock, valued at approximately $387,000.
Other hedge funds have also modified their holdings of the company. Grove Bank & Trust boosted its position in Hologic by 115.8% in the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after buying an additional 1,535 shares during the period. NuWave Investment Management LLC purchased a new position in Hologic in the 4th quarter valued at approximately $199,000. Fiduciary Trust Co. purchased a new position in Hologic in the 4th quarter valued at approximately $208,000. Advisor Partners LLC purchased a new position in Hologic in the 4th quarter valued at approximately $209,000. Finally, MPS Loria Financial Planners LLC purchased a new position in Hologic in the 4th quarter valued at approximately $214,000. 97.59% of the stock is owned by institutional investors.
In related news, Director Charles J. Dockendorff purchased 13,000 shares of Hologic stock in a transaction that occurred on Thursday, March 15th. The stock was purchased at an average cost of $38.80 per share, with a total value of $504,400.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Namal Nawana purchased 6,600 shares of Hologic stock in a transaction that occurred on Tuesday, February 13th. The stock was bought at an average cost of $37.88 per share, with a total value of $250,008.00. Following the completion of the transaction, the director now owns 6,954 shares of the company’s stock, valued at $263,417.52. The disclosure for this purchase can be found here. 0.79% of the stock is owned by insiders.
Several equities analysts have commented on the stock. BidaskClub cut shares of Hologic from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Evercore ISI assumed coverage on shares of Hologic in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $50.00 price target for the company. Cowen raised shares of Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price target for the company in a research report on Monday, December 11th. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Hologic in a research report on Friday, February 9th. Finally, Stifel Nicolaus cut shares of Hologic from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $45.00 to $42.00 in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $48.00.
Shares of Hologic, Inc. (NASDAQ:HOLX) opened at $38.46 on Friday. The stock has a market cap of $10,635.30, a price-to-earnings ratio of 18.76, a PEG ratio of 1.73 and a beta of 0.84. Hologic, Inc. has a 1 year low of $35.33 and a 1 year high of $46.80. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.05. The business had revenue of $791.10 million during the quarter, compared to analysts’ expectations of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.52 EPS. research analysts anticipate that Hologic, Inc. will post 2.25 earnings per share for the current year.
WARNING: “OLD Mission Capital LLC Purchases New Stake in Hologic, Inc. (HOLX)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/03/18/old-mission-capital-llc-purchases-new-stake-in-hologic-inc-holx.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.